Search | Clinical Trials Finder

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 3:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1825–1848 of 4,610 matching trials from the local directory fallback.

Filters: Intervention: 1 Clear all

Conditions: Gulf War Syndrome, Mitochondrial Disorder, Respiratory Chain, Persian Gulf Syndrome
Interventions: PharmaNord Bio-Quinone Active CoQ10 Gold 100mg, PharmaNord Placebo; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 50 Years and older
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Healthy
Interventions: Hyperpolarized Xe129; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 25 Years to 35 Years
Enrollment: 260 participants
Timeline: 2023 – 2027
U.S. locations: 6
States / cities: Chicago, Illinois • Iowa City, Iowa • Kansas City, Kansas + 2 more

Conditions: Lumbar Spine Degeneration, Lumbar Spine Spondylosis, Pain, Postoperative, Spine Fusion
Interventions: Placebo, Zolpidem Tartrate 10 mg; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 75 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Focus of the Study: Safety of XFB19
Interventions: Placebo, XFB19; Drug
Lead sponsor: Xfibra, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Congenital Hyperinsulinism
Interventions: 18F-Fluoro Dopa Imaging; Drug
Lead sponsor: Miguel Pampaloni; Other
Eligibility: 0 Days to 18 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Lung Inflammation
Interventions: Cu-DOTA-ECL1i; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 21 Years and older
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Recurrent Prostate Cancer
Interventions: SpectraCure P18 System, Verteporfin; Device · Drug
Lead sponsor: SpectraCure AB; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Preeclampsia (PE), Pregnancy
Interventions: 17 OHPC; Drug
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Moderate to Severe Atopic Dermatitis
Interventions: SYX-5219 Oral Capsule; Drug
Lead sponsor: Sitryx Therapeutics Ltd; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 149 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 6
States / cities: Arkansas City, Arkansas • Fremont, California • Plainfield, Indiana + 3 more

Conditions: Localized Prostate Carcinoma, Prostate Cancer
Interventions: Hyperpolarized 13C,15N2-urea, Hyperpolarized 13C-Pyruvate, Magnetic Resonance Spectroscopic Imaging; Drug · Procedure
Lead sponsor: Ivan de Kouchkovsky, MD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Control Condition, Type 2 Diabetes
Interventions: 12 week progressive exercise training; Other
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 65 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Urbana, Illinois

Conditions: Anesthesia, Endotracheal
Interventions: Direct Laryngoscope (DL), Endotracheal Tube (ETT) 180, Video laryngoscope (VL); Device · Procedure
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Type 1 Diabetes Mellitus With Hypoglycemia
Interventions: Placebo, ZT-01, 15 mg, ZT-01, 22 mg, ZT-01, 7 mg; Drug
Lead sponsor: Zucara Therapeutics Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 38
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Escondido, California + 34 more

Conditions: Anhedonia, Depression, Psychosis
Interventions: Matching Placebo Patch, Micronized Progesterone, Raclopride C11, Transdermal Estradiol; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 45 Years to 55 Years · Female only
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Recurrent WHO Grade III Glioma, Recurrent World Health Organization (WHO) Grade II Glioma, WHO Grade II Glioma, WHO Grade III Glioma
Interventions: Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Imaging, Magnetic Resonance Spectroscopic Imaging; Drug · Procedure
Lead sponsor: Susan Chang; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Neuroendocrine Carcinoma, Neuroendocrine Tumors
Interventions: Ipilimumab, Nivolumab, Seneca Valley Virus-001 (SVV-001); Drug · Biological
Lead sponsor: Peter Hosein, MD; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Malignant Brain Neoplasm
Interventions: Computed Tomography, Fluorodopa F 18, Positron Emission Tomography; Procedure · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Multiple Sclerosis
Interventions: Radiotracer [11C]-CS1P1, Radiotracer [11C]-DPA-713, Radiotracer [12F]-FDG, anti-CD20 MS treatment; Radiation · Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Advanced Solid Tumors, Clear-Cell Renal-Cell Carcinoma (ccRCC), Melanoma
Interventions: Cemiplimab, REGN10597; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 11
States / cities: Los Angeles, California • San Francisco, California • North Haven, Connecticut + 7 more

Conditions: Schizophrenia
Interventions: Buprenorphine 0.15 MG [Belbuca], Placebo; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Chronic Limb-Threatening Ischemia Nos of Native Arteries of Extremities, Peripheral Arterial Disease
Interventions: Plain (Uncoated) Balloon Angioplasty (PTA), SELUTION SLR™ DEB 014; Device
Lead sponsor: M.A. Med Alliance S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 30
States / cities: Chandler, Arizona • Jonesboro, Arkansas • Little Rock, Arkansas + 26 more

Conditions: Blood Loss, Surgical, Degenerative Lumbar Spinal Stenosis, Spinal Deformity
Interventions: Placebo, Tranexamic Acid 100 MG/ML; Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Exercise Performance of Fit Athletes, Iron Deficiencies, Iron Deficiency, Low Ferritin
Interventions: Iron Supplementation (5 mg), Lactoferrin 100 mg, Lactoferrin 300 mg; Dietary Supplement
Lead sponsor: Lindenwood University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: DERMATOMYOSITIS OR POLYMYOSITIS, Idiopathic Inflammatory Myositis (IIM)
Interventions: Placebo (no cells), ULSC (1.5 x 10^8 cells/dose); Biological
Lead sponsor: Restem, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Gainesville, Florida • Miami, Florida

Search by objective public record fields.

Coenzyme Q10 for Gulf War Illness: A Replication Study

Hyperpolarized 129Xe MRI Lung Health Cohort

The Effect of Zolpidem on Outcomes Following Lumbar Spine Fusion

A First in Human Study of the Safety, Tolerability, and the Physiologically Based Pharmacokinetics of XFB19 in Healthy Adult Volunteers.

18FluoroLDOPA PET Imaging for the Detection and Localization of Focal Congenital Hyperinsulinism

PET Imaging CCR2 in Lung Inflammation

Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System

Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe/Superimposed Preeclampsia

A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis

Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer

Exercise and Protein Efficiency in T2D

Endotracheal Tube (ETT) 180: Stylet-loaded Endotracheal Tube Rotation Before Insertion

A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes

Examining the Effects of Estradiol on Neural and Molecular Response to Reward

Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma

SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)

An Investigational Scan (18F-DOPA PET/CT) for Improving the Clinical Management of Brain Tumors

Smoldering Inflammation in MS

A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia

SELUTION4BTK Trial

Tranexamic Acid in Adult Spinal Deformity Surgery

A Pilot Study to Evaluate the Ability of Lactoferrin to Modulate Iron Homeostasis and Exercise Performance in Exercising Females

Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)